229. 肺胞蛋白症(自己免疫性又は先天性) [臨床試験数:35,薬物数:30(DrugBank:8),標的遺伝子数:3,標的パスウェイ数:12

Searched query = "Autoimmune pulmonary alveolar proteinosis", "Congenital pulmonary alveolar proteinosis", "Hereditary pulmonary alveolar proteinosis", "Pulmonary alveolar proteinosis", "PAP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01842386April 29, 201425/4/2013Rituximab for Anti-cytokine Autoantibody-Associated DiseasesRituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated DiseasesPulmonary Alveolar Proteinosis (PAP);Severe Mucocutaneous CandidoasisDrug: RituximabNational Institute of Allergy and Infectious Diseases (NIAID)NULLActive, not recruiting18 YearsN/AAll7Phase 1United States
2NCT00552461January 200731/10/2007Prospective Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisProspective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisPulmonary Alveolar Proteinosis;Primary DiseaseDrug: rituximabEast Carolina UniversityGenentech, Inc.Recruiting18 YearsN/ABoth10Phase 2United States